Merck Statement on FDA Advisory Committee Meeting About Sugammadex Sodium Injection
July 16, 2013 11:01 am ET
Merck (NYSE: MRK), known as MSD outside the United States and Canada,
confirmed today that the U.S. Food and Drug Administration (FDA) has
cancelled Thursday’s discussion of sugammadex at the Anesthetic and
Analgesic Drug Products Advisory Committee (AADPAC). Sugammadex sodium
injection is Merck’s investigational medicine for the reversal of
neuromuscular blockade (NMB) induced by rocuronium or vecuronium.
The FDA advised Merck that the agency needs additional time to assess
the results of the FDA’s recently completed inspection of a clinical
trial site. The site was one of four sites that conducted the
hypersensitivity study previously requested by the agency. Merck is
engaged in discussions with the FDA to identify the steps necessary to
enable the agency to complete its review.
“Merck believes that sugammadex is an important treatment option for an
unmet medical need in anesthesia, and we will work with the FDA on the
next steps to bring this innovation forward to patients in the United
States,” said David Michelson, M.D., head of global clinical development
for neuroscience, Merck Research Laboratories.
Sugammadex is marketed in 40 countries other than the U.S., and more
than five million vials of sugammadex have been sold as of March 2013.
Today’s Merck is a global healthcare leader working to help the world be
well. Merck is known as MSD outside the United States and Canada.
Through our prescription medicines, vaccines, biologic therapies, and
consumer care and animal health products, we work with customers and
operate in more than 140 countries to deliver innovative health
solutions. We also demonstrate our commitment to increasing access to
healthcare through far-reaching policies, programs and partnerships. For
more information, visit www.merck.com
and connect with us on Twitter,
This news release includes “forward-looking statements” within the
meaning of the safe harbor provisions of the United States Private
Securities Litigation Reform Act of 1995. These statements are based
upon the current beliefs and expectations of Merck’s management and are
subject to significant risks and uncertainties. There can be no
guarantees with respect to pipeline products that the products will
receive the necessary regulatory approvals or that they will prove to be
commercially successful. If underlying assumptions prove inaccurate or
risks or uncertainties materialize, actual results may differ materially
from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry
conditions and competition; general economic factors, including interest
rate and currency exchange rate fluctuations; the impact of
pharmaceutical industry regulation and health care legislation in the
United States and internationally; global trends toward health care cost
containment; technological advances, new products and patents attained
by competitors; challenges inherent in new product development,
including obtaining regulatory approval; Merck’s ability to accurately
predict future market conditions; manufacturing difficulties or delays;
financial instability of international economies and sovereign risk;
dependence on the effectiveness of Merck’s patents and other protections
for innovative products; and the exposure to litigation, including
patent litigation, and/or regulatory actions.
Merck undertakes no obligation to publicly update any forward-looking
statement, whether as a result of new information, future events or
otherwise. Additional factors that could cause results to differ
materially from those described in the forward-looking statements can be
found in Merck’s 2012 Annual Report on Form 10-K and the company’s other
filings with the Securities and Exchange Commission (SEC) available at
the SEC’s Internet site (www.sec.gov).
Pam Eisele, 908-423-5042
Sarra Herzog, 908-423-6154
Carol Ferguson, 908-423-4465
Justin Holko, 908-423-5088